Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

Author： Breccia Massimo   Alimena Giuliana  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.3, 2011-06, pp. : 147-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasatinib: In Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

By Keam Susan J.  

BioDrugs, Vol. 22, Iss. 1, 2008-01 ,pp. : 59-69

Adis International

Access to resources Recommend Favorite

Spotlight on Dasatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia†

By McCormack Paul L.   Keam Susan J.  

BioDrugs, Vol. 26, Iss. 1, 2012-02 ,pp. : 61-64

Adis International

Access to resources Recommend Favorite

Spotlight on Imatinib Mesylate in Chronic Myeloid Leukemia

By Curran M.P.   Croom K.F.   Goa K.L.  

BioDrugs, Vol. 18, Iss. 3, 2004-01 ,pp. : 207-210

Adis International

Access to resources Recommend Favorite

Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia

By Robak Tadeusz  

BioDrugs, Vol. 19, Iss. 1, 2005-01 ,pp. : 9-22

Adis International

Access to resources Recommend Favorite

A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia

By  

Clinical Case Reports, Vol. 3, Iss. 6, 2015-06 ,pp. : 448-452

John Wiley & Sons Inc

Access to resources Recommend Favorite